Ana Catarina Silva

Die Suchergebnisse bei Legimi sind auf die vom Nutzer angegebenen Suchkriterien zugeschnitten. Wir versuchen Titel, die für unsere Nutzer von besonderem Interesse sein könnten, durch die Bezeichnung "Bestseller" oder "Neuheit" hervorzuheben. Titel in der Liste der Suchergebnisse können auch sortiert werden - die Sortierauswahl hat Vorrang vor anderen Ergebnissen."

Ana Catarina Silva is an Associate Professor of Pharmaceutical Technology and Pharmaceutical Biotechnology and Researcher at FP-I3ID, FP-BHS, Faculty of Health Sciences, University Fernando Pessoa, Porto, Portugal; and Senior Researcher at UCIBIO, Faculty of Pharmacy, University of Porto, Portugal. She has a European PhD in Pharmaceutical Sciences with specialization in Pharmaceutical Technology from the University of Porto; and a Graduation in Pharmaceutical Sciences from the University Fernando Pessoa, Porto, Portugal. Professor Silva is also the author of several works in the areas of Pharmaceutical Technology and Pharmaceutical Biotechnology (h-index of 25) with 55+ articles, 6 book chapters, 50+ posters, and 15 oral communications. She also edited 6 books in this field; and acted as invited editor of 12 special issues. Professor Silva was included in the World's Top 2% Scientists List, in 2021, 2022 and 2023, by Stanford University, USA, and served as a referee for 10+ international funding agencies and 50+ international scientific journals. She is also a member of the editorial board of the Springer book series: Advances in Biochemical Engineering/Biotechnology; and the journals Dermatological Drug Delivery from Frontiers in Drug Delivery; Chinese Chemical Letters; Current Drug Metabolism; and Biochemistry & Pharmacology: Open Access. She supervises of 6 PhD students (2 completed), 6 MSc students (5 completed), and 37 undergraduate students (34 completed). Her current research interests are focused on developing lipid-based nanosystems to improve drug delivery. In particular, nose-to-brain delivery and cutaneous delivery; the quality-by-design (QbD) approach to optimize formulations of lipid-based nanosystems; and the development of Biopharmaceuticals and Advanced Therapy Medicinal Products (ATMPs).